Beam Therapeutics Inc.
BEAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745999
In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 2 sales; 262 institutions reported holding it in 13F filings for Q3 2026, worth $2.74B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Key figures
- Market capClose on Nov 18, 2026
- $2.17B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.19M in total
- 2
- 13F holdersQ3 2026, −9 vs. previous quarter
- 262
- 13F valueReported value at the end of Q3 2026
- $2.74B
- Superinvestors holdingAt the end of Q3 2026
- 2
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $139.7M
- +120.0% year over year
- Net income, FY2025
- -$80.0M
- No comparable prior period
- Free cash flow, FY2025
- -$360.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $307.0K
- −96.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $80.0M (57.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 26.1M
- Shares sold short
- Change
- −160.7K
- −0.6% vs. previous
- Days to cover
- 13.69
- At average daily volume
Superinvestors holding BEAM, Q3 2026
Go to the superinvestors tab2 superinvestors report holding Beam Therapeutics Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
1.7%
Beam Therapeutics Inc.'s share of the portfolio
- Shares
- 11,805,372
- Value
- $288.6M
Duquesne Family Office
Stanley Druckenmiller
0.4%
Beam Therapeutics Inc.'s share of the portfolio
- Shares
- 699,700
- Value
- $17.1M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Beam Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 (view filing)8:09 PM ET | Oct 15-16 | 1 day | Evans John M.CEO | SSale | −50.0K | $23.77 | −$1.19M | −4.6%1.05M after | 2 lots10b5-1 |
| Oct 2, 2026 (view filing)4:05 PM ET | Oct 1 | 1 day | Cavanagh Bethany JSVP, Finance and Treasurer | SSale | −187 | $24.41 | −$4.56K | −0.4%51.0K after | 10b5-1 |
| Jul 29, 2026 (view filing)4:05 PM ET | Jul 27 | 2 days | Simon AmyChief Medical Officer | SSale | −16.7K | $25.74 | −$429.0K | −16.3%85.7K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:05 PM ET | Jun 30 | 2 days | Simon AmyChief Medical Officer | SSale | −373 | $34.73 | −$13.0K | −0.4%102.4K after | 10b5-1 |
| Jul 1, 2026 (view filing)4:05 PM ET | Jun 29-30 | 2 days | Evans John M.CEO | SSale | −50.0K | $34.90 | −$1.75M | −4.6%1.05M after | 4 lots10b5-1 |
| Jun 29, 2026 (view filing) | Jun 25-26 | 4 days | FMR LLC10% Owner, Other: See Remark 1 | SSale | −284.9K | $35.24 | −$10.0M | −25.0%854.6K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Evans John M.CEO | SSale | −30.1K | $24.58 | −$739.3K | −2.8%1.05M after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Simon AmyChief Medical Officer | SSale | −6.70K | $24.58 | −$164.7K | −6.1%102.7K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Cavanagh Bethany JSVP, Finance and Treasurer | SSale | −3.24K | $24.58 | −$79.7K | −6.0%51.2K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Bellon ChristineChief Legal Officer | SSale | −5.96K | $24.58 | −$146.4K | −5.1%109.7K after | 10b5-1 |
Top 10 13F holders, Q3 2026
See all 262 holdersThe largest institutional positions in Beam Therapeutics Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,926,476 | $316.1M | 0.01% | +317,474+2.5% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 11,805,372 | $288.6M | 1.66% | +1,570,510+15.3% | Added |
| Farallon Capital Management, L.L.C. | 10,276,396 | $251.3M | 1.31% | +40,000+0.4% | Added |
| BlackRock, Inc. | 9,119,097 | $223.0M | 0.00% | +121,555+1.4% | Added |
| State Street Corp | 5,920,492 | $144.8M | 0.00% | +93,370+1.6% | Added |
| Vanguard Portfolio Management LLC | 4,901,651 | $119.8M | 0.01% | −19,608−0.4% | Reduced |
| Vanguard Capital Management LLC | 4,608,292 | $112.7M | 0.00% | +8,855+0.2% | Added |
| ARCH Venture Management, LLC | 4,540,132 | $111.0M | 6.88% | 00.0% | Unchanged |
| Kynam Capital Management, LP | 3,933,894 | $96.2M | 5.33% | +1,093,102+38.5% | Added |
| Sumitomo Mitsui Trust Holdings, Inc. | 3,349,244 | $81.9M | 0.05% | −105,799−3.1% | Reduced |
Holders of 5% or more of BEAM
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Beam Therapeutics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 12.60%12.8M shares | −1.00 ppfrom 13.60% | Feb 8, 202111 filings | Feb 5, 2026 | SEC |
| ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 11.43%11.8M shares | +1.48 ppfrom 9.95% | Jun 10, 20219 filings | Nov 13, 2026 | SEC |
| Farallon Capital Management, L.L.C. | 13G/A | 9.99%10.3M shares | – | Aug 13, 20261 filing | Aug 13, 2026 | SEC |
| Farallon Capital Partners, L.P. | 13G/A | 9.99%10.1M shares | 0.00 ppfrom 9.99% | Jul 14, 20228 filings | Feb 5, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.50%7.50M shares | – | Oct 21, 20243 filings | Apr 17, 2025 | SEC |